<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540631</url>
  </required_header>
  <id_info>
    <org_study_id>AL0106ac</org_study_id>
    <secondary_id>2006-000934-11</secondary_id>
    <nct_id>NCT00540631</nct_id>
  </id_info>
  <brief_title>Multicenter Trial of Immunotherapy With House Dust Mite Allergoid</brief_title>
  <acronym>ACRI</acronym>
  <official_title>A Multicentre Randomized Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of a Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides Pteronyssinus) in Patients With Rhinitis/Rhinoconjunctivitis and/or Allergic Asthma Bronchiale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergopharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergopharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter Immunotherapy House Dust Mite Allergoid
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre randomized placebo-controlled double-blind clinical trial for evaluation of
      safety and efficacy of a specific immunotherapy with an aluminium hydroxide-adsorbed
      allergoid preparation of house dust mite (Dermatophagoides pteronyssinus) in patients with
      rhinitis/rhinoconjunctivitis and/or allergic asthma bronchiale
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the change of the area under the curve (AUC)of the Symptom-Medication-Score (SMS)after 2 years of double-blind treatment to baseline</measure>
    <time_frame>November 2007 - February 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the AUC of the SMS after one year to baseline.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Nasal Eosinophil Cationic Protein (ECP) after 2 years to baseline</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic changes IgE, IgG1 and IgG4</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety of treatments during the entire study period</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>subcutaneous treatment with placebo Placebo- physiological saline containing histamine-dihydrochloride 0.1mL, 0.2mL, 0.4mL, 0.6mL of strength A(1000TU/mL) followed by 0.1mL, 0.4mL, 0.6mL by strength B (10000TU/mL) in weekly intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment with house dust mite extract</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)</intervention_name>
    <description>Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection
to be det. A 0.1 100 TU
7 (+7) days later A 0.2 200 TU
7 (+7) days later A 0.4 400 TU
7 (+7) days later A 0.6 600 TU
7 (+7) days later B 0.1 1000 TU
7 (+7) days later B 0.2 2000 TU
7 (+7) days later B 0.4 4000 TU
7 (+7) days later B 0.6 6000 TU
Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection
to be det. A 0.1 100 TU
7 (+7) days later A 0.2 200 TU
7 (+7) days later A 0.4 400 TU
7 (+7) days later A 0.6 600 TU
7 (+7) days later B 0.1 1000 TU
7 (+7) days later B 0.2 2000 TU
7 (+7) days later B 0.4 4000 TU
7 (+7) days later B 0.6 6000 TU
Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive SPT

          -  Positive EAST

          -  Positive specific provocation test

        Exclusion Criteria:

          -  Serious chronic diseases

          -  other perennial allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Riechelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ulm, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergopharma GmbH &amp; Co. KG</name>
      <address>
        <city>Reinbek</city>
        <zip>21465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.allergopharma.de</url>
    <description>leader in specific allergy research and therapy</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>House Dust Mite Allergen</keyword>
  <keyword>Aluminium hydroxide-adsorbed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

